Cervical Cancer

Cancer remains the main use of Vilac Plus over the world since the publication of 3 clinical trials : Brain Tumor and Lung Cancer in 2006, then Cervical Cancer in 2007. The antiradical effectiveness of Vilac Plus had already been proved In Vitro (KRL Test).

Breast and Cervical Cancer, Vilac Plus closing campaign

Campaign Closing and presentation of the excellent results of patients treated with Vilac Plus products in the program Que no Me Pierda with John Arandia, Canal 11 Red ONE, Bolivia. Tuesday May 4, 2010. With the scientific opinion of Dr. Luciano Gutierrez, eminent obstetrician and gynecologist oncologist well known in South America.

(more…)

TV Testimony : Cervix Cancer

Testimony of a patient with cervix cancer. She received treatment with the Vilac Plus drink.
Testimony released by the program “Junto con la Justa”, Channel 7, TV Bolivia, La Paz – Bolivia.

QNMP Campain Against Cancer, Intermediate Report November 5th, 2009

Reporte intermedio de la Campaña contra el Cancer cervicouterino y cancer de mama en 10 pacientes. Programa televisivo Que no me Pierda. 5 de noviembre de 2009. Participación externa del Ginecólogo Luciano Gutierrez.

(more…)

Second campain QNMP against cancer : first testimonies (3 videos)

Symbolic delivery of 100 liters of Vilac Plus Eubiotic drink for the Second Campaign Against Breast Cancer and Cervical Cancer in the television program “Que no me Pierda” on Thursday, 10 September 2009.

(more…)

Second Vilac Plus Campain QNMP

The second Vilac Plus campaign against cervical cancer and breast cancer was launched on 13 July 2009.
The campaign is funded by Solayni, Vilac Plus distributor in South America, and supported by the most important television show in Bolivia, QNMP (Que No Me Pierda).

(more…)

Cervical Cancer – Clinical Trials

Evaluation of the effectiveness of the product the Vilac Plus® Eubiotic Drink G716/45 on Cancers Stage IIIB and IV.

Palliative treatment of advanced cervical cancer with radiotherapy and Thai herbal medicine as supportive remedy

Clinical trials HE480745 conducted at Srinagarind Public Hospital, Faculty of Medicine, Khon Kaen University, Thailand. Published in The Asean Journal of Radiology, September – December 2007.

Abstract

Objective

To evaluate the supportive effect of Thai herbal medicine, Vilac Plus (G716/45) on standard radiotherapy in comparison with historic control from the literature reports the results of treatment in stage IIIB-IV cervical cancer.

Patients and Methods

During the period of March 2003 to June 2005. Thirty patients in advanced cervical cancer stage IIIB-IV with poor performance status were treated by palliative radiotherapy in adjuvant with the Thai herbal tonic solution (Vilac Plus G716/45) daily dose 15-30 ml orally tid, pc as an additional supportive remedy.

Results

Thirty cases of patients in advanced cervical cancer stage IIIB-IV with poor performance status, the median age in stage IIIB, IVA, IVB were 50 years (range 41-73 years), 50.5 years (45 years, 58 years), 69 years (67 years, 71 years) respectively. The analysis were being categorized and performed on stages IIIB, IVA, IVA with bladder cancer and IVB reporting in corresponding number of cases/total subject (percentage) were 25/30 (83.33%), 2/30 (6.67%), 1/30 (3.33%) and 2/30 (6.67%) respectively. The median tumor size for stages IIIB, IVA and IVB were 5 cm (range 2-10 cm), 5 cm (4,6 cm) and 4 cm (2,6 cm) respectively. The pathological identification had been classified to be squamous cell carcinomas 21/30 (70.00%), adenocarcinomas 7/30 (23.33%), small cell carcinoma 1/30 case (3.33%) and clinically staging IIIB 1/30 case (3.33%). The median time interval between teletherapy and brachtytherapy was 22 days (range 7-41 days). Eventually, 84% of the stage IIIB cases were undergone by prolonged gap of more than 2 weeks of time interval between teletherapy and brachytherapy while the rest of the case (16%) received the optimal time gap of treatments. The initial complete response and partial response after 4-6 weeks of radiotherapy were 84% and 16% respectively. The patterns of failure in stage IIIB revealed in 16% with residual pelvic diseases (< 6 months), 3% with local pelvic recurrence (> 6 months) and 4% with distant metastases. Median follow-up period in stage IIIB was 22 months (range 2-48 months). Low radiation complications were noted, the severe radiation proctitis (grade 3) was found to be 3.33%. It was notable results in the declined BUN/Cr level in cervical cancer patients with underlying renal insufficiency/chronic renal failure patients treated by palliative radiotherapy and Thai herbal tonic solution as an additional supportive remedy had been observed in 2 cases of stage IIIB and 1 case of stage IVA with neither surgical intervention nor hemodialysis.

Conclusion

Our preliminary study in the treatment of advanced cases of Ca. Cervix with palliative radiotherapy and Thai herbal medicine had shown the evidence of initial complete regression of tumour with disappearance of foul smell discharge as high as 84% with low rate of local pelvic recurrence, low distant metastases and low rate of radiation complication. However, the study had a limitation on the number of cases and a short follow up period. Moreover, this treatment modality had shown the benefit on the declination of BUN/Cr level in some cases of those locally advanced stages III B-IV in chronic renal failure caused by chronic ureteric obstruction due to lateral spreading of the cancer pressing on both ureters, without neither surgical intervention nor hemodialysis. The declined BUN/Cr levels were the consequence of the relief of pressure effect on the ureters by the decreasing of the tumour volumes. Palliative radiotherapy with Thai herbal tonic as supportive remedy was safe, cost effective, in addition to the benefit of improval of quality of life without the toxicity of herbal medicine. Therefore, this combination of palliative radiotherapy together with Thai Herbal Medicine would be the alternative option for the palliative treatment of advanced cancer cases with poor performance status or in locally advanced cancer cases. Further studies should be performed in order to confirm this findings with statistical significant conclusion.

Montien PESEE M.D, Wichit KIRDPON Ph.D, Sukachart KIRDPON M.D, Anucha PUAPAIROJ M.D and Pongsiri PRATHNADI M.D

Download